Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

OLMA | Olema Pharmaceuticals Inc

Index	RUT	P/E	-	EPS (ttm)	-2.41	Insider Own	11.49%	Shs Outstand	40.29M	Perf Week	-11.24%
Market Cap	473.46M	Forward P/E	-	EPS next Y	-2.23	Insider Trans	41.82%	Shs Float	36.60M	Perf Month	-9.70%
Income	-97.28M	PEG	-	EPS next Q	-0.49	Inst Own	96.97%	Short Float / Ratio	4.81% / 6.20	Perf Quarter	26.80%
Sales	0.00M	P/S	-	EPS this Y	16.40%	Inst Trans	-1.79%	Short Interest	1.76M	Perf Half Y	253.40%
Book/sh	3.93	P/B	2.91	EPS next Y	-1.62%	ROA	-45.43%	Target Price	21.57	Perf Year	293.47%
Cash/sh	4.05	P/C	2.83	EPS next 5Y	-	ROE	-48.90%	52W Range	2.19 - 13.50	Perf YTD	367.35%
Dividend	-	P/FCF	-	EPS past 5Y	-158.58%	ROI	-59.76%	52W High	-15.19%	Beta	2.45
Dividend %	-	Quick Ratio	11.56	Sales past 5Y	0.00%	Gross Margin	-	52W Low	422.83%	ATR	0.87
Employees	86	Current Ratio	11.56	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	47.71	Volatility	8.09% 7.30%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	40.04%	Profit Margin	-	Rel Volume	0.88	Prev Close	11.25
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Aug 08 AMC	Payout	-	Avg Volume	284.07K	Price	11.45
Recom	1.12	SMA20	-6.51%	SMA50	7.50%	SMA200	73.59%	Volume	249,424	Change	1.78%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-23	Initiated	Oppenheimer	Outperform	$21
May-05-23	Initiated	CapitalOne	Overweight	$16
Feb-22-23	Initiated	Credit Suisse	Outperform	$12
Jul-06-22	Resumed	Canaccord Genuity	Buy	$16
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight	$52
Dec-14-20	Initiated	Jefferies	Buy	$70
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy	$60

Oct-03-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-25-23 09:55AM	Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect? (Zacks)
08:50AM	Here's What Could Help Olema Pharmaceuticals, Inc. (OLMA) Maintain Its Recent Price Strength (Zacks)
Sep-20-23 07:29AM	Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
01:09PM	Loading…
Sep-15-23 01:09PM	BIOTECHNOLOGY VALUE FUND L P Acquires Stake in Olema Pharmaceuticals Inc (GuruFocus.com) +6.09%
Sep-14-23 11:02PM	Insider Buying: BIOTECHNOLOGY VALUE FUND L P Acquires 1,505,932 Shares of Olema Pharmaceuticals Inc (GuruFocus.com)
Sep-08-23 12:00PM	What Makes Olema Pharmaceuticals, Inc. (OLMA) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 91.97% Upside in Olema Pharmaceuticals, Inc. (OLMA): Here's What You Should Know (Zacks)
Sep-07-23 04:02PM	The 7 Best Small-Cap Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-06-23 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.02%
Sep-05-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +19.51%
07:30AM	Olema Oncology Announces Combined Financing for Up to $180 Million (GlobeNewswire)
Aug-08-23 04:03PM	Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:23AM	Here's Why We're Watching Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation (Simply Wall St.)
04:30PM	Loading…
Aug-02-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.05%
Aug-01-23 08:00AM	Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-05-23 07:30AM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-23 01:00PM	3 Small-Cap Biotech Stocks With Positive Momentum (TheStreet.com)
Jun-02-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-23 04:30PM	Olema Oncology to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-19-23 06:29AM	Institutional investors own a significant stake of 42% in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) (Simply Wall St.)
May-11-23 08:43AM	Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study (GlobeNewswire)
May-09-23 04:01PM	Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +10.65%
May-08-23 07:06AM	Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress (GlobeNewswire)
May-02-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-13-23 04:30PM	Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference (GlobeNewswire) +7.67%
Apr-04-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.16%
Mar-09-23 04:00PM	Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update (GlobeNewswire)
Mar-02-23 05:00PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Loading…
04:05PM	Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-21-23 04:30PM	Olema Oncology to Participate at Upcoming Investor Conferences (GlobeNewswire) -8.57%
Feb-02-23 06:00PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-03-23 07:00AM	Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.76%
Jan-02-23 08:23AM	We Think Olema Pharmaceuticals (NASDAQ:OLMA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Dec-07-22 03:37PM	Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study (GlobeNewswire) +5.22%
Dec-02-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-22 09:16AM	Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)
Nov-08-22 04:30PM	Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-01-22 08:00AM	Olema Oncology to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-26-22 08:01AM	Olema Pharma Says Lead Candidate Robust Activity In Breast Cancer Patients (Benzinga) +5.04%
03:00AM	Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial (GlobeNewswire)
Oct-12-22 07:01AM	Olema Oncology Announces Upcoming Clinical Data Poster Presentation at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -5.33%
Oct-04-22 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-06-22 04:30PM	Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-01-22 05:01PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.58%
Aug-09-22 04:35PM	Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
04:30PM	Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer (GlobeNewswire)
Aug-04-22 04:30PM	Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire)
Aug-03-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.10%
Jul-26-22 07:32AM	Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-22-22 06:49AM	Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug (Zacks) -14.44%
Jul-21-22 07:30AM	Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer (GlobeNewswire) +20.59%
Jul-07-22 10:40AM	2 Strong Buy Penny Stocks That Could See Huge Long-Term Gains (TipRanks) +8.32%
Jul-05-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.18%
Jun-09-22 07:35AM	Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program (GlobeNewswire) +8.50%
07:30AM	Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies (GlobeNewswire)
Jun-02-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-24-22 04:30PM	Olema Oncology to Present at Jefferies Healthcare Conference (GlobeNewswire) +10.13%
May-09-22 04:30PM	Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.62%
May-03-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-18-22 04:30PM	Olema Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-04-22 07:30AM	Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire) +5.37%
Mar-08-22 04:35PM	Olema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire)
Feb-28-22 04:30PM	Olema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-22-22 07:30AM	Olema Oncology to Present at Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-16-22 10:06AM	We're Hopeful That Olema Pharmaceuticals (NASDAQ:OLMA) Will Use Its Cash Wisely (Simply Wall St.)
Feb-03-22 05:00PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.27%
Jan-31-22 07:30AM	Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer (GlobeNewswire) +9.35%
Jan-04-22 07:30AM	Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.83%
Dec-16-21 12:38PM	Tybourne Capital Management (hk) Ltd Buys Snowflake Inc, Pinduoduo Inc, KE Holdings Inc, Sells ... (GuruFocus.com)
Dec-01-21 04:09PM	Has Olema Stock Hit Bottom? JPMorgan Sees a Silver Lining (TipRanks) +8.34%
Nov-30-21 11:02AM	OLMA Stock: The Breast Cancer Therapy News That Has Olema Pharmaceuticals Plunging Today (InvestorPlace) -60.02%
07:00AM	Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer (GlobeNewswire)
Nov-29-21 04:27PM	Olema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media (GlobeNewswire)
Nov-22-21 07:30AM	Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.63%
Nov-19-21 12:00PM	33 Stocks Moving In Friday's Mid-Day Session (Benzinga) -8.67%
Nov-10-21 04:05PM	Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-21 07:30AM	Olema Oncology to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Oct-18-21 11:01AM	Notable Olema Pharmaceuticals Insider Trades $175K In Company Stock (Benzinga) -7.20%
Oct-13-21 11:43AM	Chief Business Officer Of Olema Pharmaceuticals Trades $155K In Company Stock (Benzinga)
Sep-30-21 05:00PM	Olema Oncology Announces Trials in Progress Poster on OP-1250 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-09-21 07:30AM	Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference (GlobeNewswire)
Aug-30-21 04:05PM	Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire)
Aug-18-21 10:46AM	Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth (Simply Wall St.)
Aug-10-21 04:05PM	Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-28-21 04:05PM	Olema Oncology to Present at Canaccord Genuity 41st Annual Growth Conference (GlobeNewswire)
May-18-21 04:05PM	Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference (GlobeNewswire)
May-11-21 04:05PM	Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-07-21 07:30AM	Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire) -6.20%
Apr-06-21 07:30AM	Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors (GlobeNewswire) -8.28%
Mar-17-21 04:05PM	Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-10-21 04:45PM	Olema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 (GlobeNewswire) +8.82%
Feb-23-21 07:00AM	Olema Oncology to Participate at Upcoming Virtual Investor Conferences (GlobeNewswire) -15.01%
Feb-19-21 04:59AM	We're Hopeful That Olema Pharmaceuticals (NASDAQ:OLMA) Will Use Its Cash Wisely (Simply Wall St.) +7.07%
Dec-31-20 03:42PM	Biotech IPO Frenzy Brings in 3 Stocks to Buy (TipRanks)
Dec-17-20 07:00AM	Olema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference (GlobeNewswire) +8.03%
Dec-07-20 07:39AM	Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 (GlobeNewswire) -8.31%

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harmon Cyrus	Director	Sep 29	Sale	12.41	25,000	310,250	973,714	Oct 03 05:00 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Sep 19	Sale	12.67	20,000	253,400	572,011	Sep 21 05:00 PM
BVF PARTNERS L P/IL	Director	Sep 12	Buy	9.84	1,505,932	14,818,371	4,688,954	Sep 14 04:25 PM
Harmon Cyrus	Director	Sep 05	Sale	11.62	10,000	116,200	998,714	Sep 05 09:08 PM
Harmon Cyrus	Director	Aug 31	Sale	9.36	15,000	140,400	1,008,714	Sep 05 09:08 PM
Harmon Cyrus	Director	Aug 16	Sale	10.14	15,000	152,100	1,023,714	Aug 17 05:00 PM
Harmon Cyrus	Director	Jun 08	Sale	6.30	10,000	63,000	1,038,714	Jun 09 05:30 PM
Harmon Cyrus	Director	Jun 06	Sale	6.29	5,000	31,475	1,048,714	Jun 07 09:30 PM
Harmon Cyrus	Director	Jun 05	Sale	6.04	5,000	30,225	1,053,714	Jun 07 09:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OLMA | Olema Pharmaceuticals Inc

Upgrade your FINVIZ experience